Prior Marguerite, Goldberg Joshua, Chiruta Chandramouli, Farrokhi Catherine, Kopynets Mariya, Roberts Amanda J, Schubert David
The Salk Institute for Biological Studies, Cellular Neurobiology, La Jolla, CA, USA.
Behavior Testing Core, The Salk Institute for Biological Studies, La Jolla, CA, USA.
Alzheimers Dement. 2016 Jun;12(6):678-86. doi: 10.1016/j.jalz.2016.03.016. Epub 2016 May 2.
Neurons die in Alzheimer's disease (AD) and are not effectively replaced. An alternative approach to maintain nerve cell number is to identify compounds that stimulate the proliferation of endogenous neural stem cells in old individuals to replace lost neurons. However, unless a neurogenic drug is also neuroprotective, the replacement of lost neurons will not be sufficient to stop disease progression.
The neuroprotective AD drug candidate J147 is shown to enhance memory, improve dendritic structure, and stimulate cell division in germinal regions of the brains of very old mice. Based on the potential neurogenic potential of J147, a neuronal stem cell screening assay was developed to optimize derivatives of J147 for human neurogenesis.
The best derivative of J147, CAD-031, maintains the neuroprotective and memory enhancing properties of J147, yet is more active in the human neural stem cell assays.
The combined properties of neuroprotection, neurogenesis, and memory enhancement in a single drug are more likely to be effective for the treatment of age-associated neurodegenerative disorders than any individual activity alone.
在阿尔茨海默病(AD)中神经元会死亡且无法有效替代。维持神经细胞数量的另一种方法是鉴定出能刺激老年个体内源性神经干细胞增殖以替代丢失神经元的化合物。然而,除非一种神经生成药物同时具有神经保护作用,否则丢失神经元的替代不足以阻止疾病进展。
神经保护类AD候选药物J147被证明可增强极老龄小鼠大脑生发区的记忆力、改善树突结构并刺激细胞分裂。基于J147潜在的神经生成潜力,开发了一种神经干细胞筛选试验以优化J147用于人类神经生成的衍生物。
J147的最佳衍生物CAD - 031保留了J147的神经保护和增强记忆特性,但在人类神经干细胞试验中活性更高。
单一药物兼具神经保护、神经生成和增强记忆的特性,相比于任何单一活性,更有可能有效治疗与年龄相关的神经退行性疾病。